Dexcom Shares Outstanding History (DXCM)
Dexcom reported 384.8M shares outstanding at the end of fiscal 2025.
View full Dexcom company overviewDexcom annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 384.8M | −5.9M | −1.51% |
| 2024 | 2024-12-31 | 390.7M | 5.3M | +1.38% |
| 2023 | 2023-12-31 | 385.4M | −900,000 | −0.23% |
| 2022 | 2022-12-31 | 386.3M | −1.7M | −0.44% |
| 2021 | 2021-12-31 | 388.0M | −24.21B | −98.42% |
| 2020 | 2020-12-31 | 24.60B | −69.20B | −73.77% |
| 2019 | 2019-12-31 | 93.80B | −274.84B | −74.56% |
| 2018 | 2018-12-31 | 368.64B | 12.29B | +3.45% |
| 2017 | 2017-12-31 | 356.35B | 9.83B | +2.84% |
| 2016 | 2016-12-31 | 346.52B | 11.88B | +3.55% |
| 2015 | 2015-12-31 | 334.64B | 18.02B | +5.69% |
| 2014 | 2014-12-31 | 316.62B | 19.66B | +6.62% |
| 2013 | 2013-12-31 | 296.96B | 12.29B | +4.32% |
| 2012 | 2012-12-31 | 284.67B | 8.19B | +2.96% |
| 2011 | 2011-12-31 | 276.48B | 22.21B | +8.73% |
| 2010 | 2010-12-31 | 254.27B | — | — |
Dexcom quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 377.4M | −14.8M | −3.77% |
| Q1 2026 | 2026-03-31 | 385.9M | −6.2M | −1.58% |
| Q4 2025 | 2025-12-31 | 384.8M | −5.9M | −1.51% |
| Q3 2025 | 2025-09-30 | 390.0M | −600,000 | −0.15% |
| Q2 2025 | 2025-06-30 | 392.2M | −8.5M | −2.12% |
| Q1 2025 | 2025-03-31 | 392.1M | −4.0M | −1.01% |
| Q4 2024 | 2024-12-31 | 390.7M | 5.3M | +1.38% |
| Q3 2024 | 2024-09-30 | 390.6M | 4.2M | +1.09% |
| Q2 2024 | 2024-06-30 | 400.7M | 14.6M | +3.78% |
| Q1 2024 | 2024-03-31 | 396.1M | 8.5M | +2.19% |
| Q4 2023 | 2023-12-31 | 385.4M | −900,000 | −0.23% |
| Q3 2023 | 2023-09-30 | 386.4M | 200,000 | +0.05% |
| Q2 2023 | 2023-06-30 | 386.1M | −6.5M | −1.66% |
| Q1 2023 | 2023-03-31 | 387.6M | −4.8M | −1.22% |
| Q4 2022 | 2022-12-31 | 386.3M | −1.7M | −0.44% |
| Q3 2022 | 2022-09-30 | 386.2M | −1.16B | −75.09% |
| Q2 2022 | 2022-06-30 | 392.6M | −5.80B | −93.66% |
| Q1 2022 | 2022-03-31 | 392.4M | −24.36B | −98.41% |
| Q4 2021 | 2021-12-31 | 388.0M | −24.21B | −98.42% |
| Q3 2021 | 2021-09-30 | 1.55B | −96.75B | −98.42% |
| Q2 2021 | 2021-06-30 | 6.19B | −91.50B | −93.66% |
| Q1 2021 | 2021-03-31 | 24.76B | −69.76B | −73.81% |
| Q4 2020 | 2020-12-31 | 24.60B | −69.20B | −73.77% |
| Q3 2020 | 2020-09-30 | 98.30B | −276.48B | −73.77% |
| Q2 2020 | 2020-06-30 | 97.69B | −275.87B | −73.85% |
| Q1 2020 | 2020-03-31 | 94.52B | −278.22B | −74.64% |
| Q4 2019 | 2019-12-31 | 93.80B | −274.84B | −74.56% |
| Q3 2019 | 2019-09-30 | 374.78B | 11.06B | +3.04% |
| Q2 2019 | 2019-06-30 | 373.56B | 11.47B | +3.17% |
| Q1 2019 | 2019-03-31 | 372.74B | 11.88B | +3.29% |
| Q4 2018 | 2018-12-31 | 368.64B | 12.29B | +3.45% |
| Q3 2018 | 2018-09-30 | 363.72B | 7.78B | +2.19% |
| Q2 2018 | 2018-06-30 | 362.09B | 7.78B | +2.20% |
| Q1 2018 | 2018-03-31 | 360.86B | 7.37B | +2.09% |
| Q4 2017 | 2017-12-31 | 356.35B | 9.83B | +2.84% |
| Q3 2017 | 2017-09-30 | 355.94B | 9.83B | +2.84% |
| Q2 2017 | 2017-06-30 | 354.30B | 11.06B | +3.22% |
| Q1 2017 | 2017-03-31 | 353.48B | 11.88B | +3.48% |
| Q4 2016 | 2016-12-31 | 346.52B | 11.88B | +3.55% |
| Q3 2016 | 2016-09-30 | 346.11B | 13.11B | +3.94% |
| Q2 2016 | 2016-06-30 | 343.24B | 15.56B | +4.75% |
| Q1 2016 | 2016-03-31 | 341.61B | 17.20B | +5.30% |
| Q4 2015 | 2015-12-31 | 334.64B | 18.02B | +5.69% |
| Q3 2015 | 2015-09-30 | 333.00B | 20.07B | +6.41% |
| Q2 2015 | 2015-06-30 | 327.68B | 18.84B | +6.10% |
| Q1 2015 | 2015-03-31 | 324.40B | 18.02B | +5.88% |
| Q4 2014 | 2014-12-31 | 316.62B | 19.66B | +6.62% |
| Q3 2014 | 2014-09-30 | 312.93B | 19.25B | +6.56% |
| Q2 2014 | 2014-06-30 | 308.84B | 17.20B | +5.90% |
| Q1 2014 | 2014-03-31 | 306.38B | 16.79B | +5.80% |
| Q4 2013 | 2013-12-31 | 296.96B | 12.29B | +4.32% |
| Q3 2013 | 2013-09-30 | 293.68B | 10.04B | +3.54% |
| Q2 2013 | 2013-06-30 | 291.64B | 9.40B | +3.33% |
| Q1 2013 | 2013-03-31 | 289.59B | 8.81B | +3.14% |
| Q4 2012 | 2012-12-31 | 284.67B | 7.99B | +2.89% |
| Q3 2012 | 2012-09-30 | 283.65B | 7.17B | +2.59% |
| Q2 2012 | 2012-06-30 | 282.23B | 6.45B | +2.34% |
| Q1 2012 | 2012-03-31 | 280.78B | 26.51B | +10.43% |
| Q4 2011 | 2011-12-31 | 276.68B | — | — |
| Q3 2011 | 2011-09-30 | 276.48B | — | — |
| Q2 2011 | 2011-06-30 | 275.79B | — | — |
| Q4 2010 | 2010-12-31 | 254.27B | — | — |
Dexcom shares outstanding trends
Over the last five reported fiscal years, Dexcom's shares outstanding moved from 24.60B to 384.8M, a change of −24.22B. The latest reported quarter, Q2 2026, shows 377.4M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Dexcom filings at SEC.gov ↗